SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Mersana Therapeutics, Inc. (MRSN) , forward earnings yield 4.33%.
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($3.00, 89.7%).
- Forward P/E 23.1
- Analyst consensus target $3.00 (-89.7% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 34/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MRSN
Valuation Multiples
P/E (TTM)0.0
Forward P/E23.1
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio87.99
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.56
Forward EPS (Est.)$1.26
Book Value / Share$0.00
Revenue / Share$0.33
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield4.33%
Dividend Yield0.00%
Analyst Target$3.00 (-89.7%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.94 |
$10.36M |
$-16.43M |
-158.6% |
| 2016 |
$-0.78 |
$25.17M |
$-13.7M |
-54.4% |
| 2017 |
$-3.22 |
$17.55M |
$-38.71M |
-220.6% |
| 2018 |
$-2.79 |
$10.59M |
$-64.26M |
-606.5% |
| 2019 |
$-0.63 |
$42.12M |
$-27.2M |
-64.6% |
| 2020 |
$-1.44 |
$828K |
$-88.4M |
-10676.8% |
| 2021 |
$-2.40 |
$43K |
$-169.21M |
-393500% |
| 2022 |
$-2.22 |
$26.58M |
$-207.54M |
-780.8% |
| 2023 |
$-1.48 |
$36.86M |
$-171.67M |
-465.8% |
| 2024 |
$-0.56 |
$40.5M |
$-69.19M |
-170.9% |
